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Abstract
Introduction: CD40 Ligand (CD40L) and its soluble counterpart (sCD40L) are proteins that exhibit prothrombotic
and proinflammatory properties on binding to their cell surface receptor CD40. The results of small clinical studies
suggest that sCD40L levels could play a role in sepsis; however, there are no data on the association between
sCD40L levels and mortality of septic patients. Thus, the aim of this study was to determine whether circulating
sCD40L levels could be a marker of adverse outcome in a large cohort of patients with severe sepsis.
Methods: This was a multicenter, observational and prospective study carried out in six Spanish intensive care
units. Serum levels of sCD40L, tumour necrosis factor-alpha and interleukin-10, and plasma levels of tissue factor
were measured in 186 patients with severe sepsis at the time of diagnosis. Serum sCD40L was also measured in 50
age- and sex-matched controls. Survival at 30 days was used as the endpoint.
Results: Circulating sCD40L levels were significantly higher in septic patients than in controls (P = 0.01), and in
non-survivors (n = 62) compared to survivors (n = 124) (P = 0.04). However, the levels of CD40L were not
different regarding sepsis severity. Logistic regression analysis showed that sCD40L levels >3.5 ng/mL were
associated with higher mortality at 30 days (odds ratio = 2.89; 95% confidence interval = 1.37 to 6.07; P =
0.005). The area under the curve of sCD40L levels >3.5 ng/mL as predictor of mortality at 30 days was 0.58 (95%
CI = 0.51 to 0.65; P = 0.03).
Conclusions: In conclusion, circulating sCD40L levels are increased in septic patients and are independently
associated with mortality in these patients; thus, its modulation could represent an attractive therapeutic target.
Introduction
Severe sepsis is a common, expensive, and frequently
fatal condition, leading to as many deaths annually as
acute myocardial infarction [1]. Thus, a continuous
search for new biomarkers in sepsis is necessary to aid
early diagnosis and stratification of its severity.
CD40 Ligand (CD40L) and its soluble counterpart
(sCD40L) are proteins that exhibit prothrombotic and
proinflammatory properties on binding to their cell sur-
face receptor CD40 [2,3]. CD40L is a member of the
tumour necrosis factor (TNF) family and is expressed as
a transmembrane protein in activated platelets [4,5].
CD40L exerts several pro-inflammatory [6,7] and pro-
coagulant [8-13] effects.
Higher levels of sCD40L have been found in patients
with acute coronary syndrome [14,15], stroke [16], sys-
temic lupus erythematosus [17], and chronic lymphocy-
tic leukemia [18]. The role of sCD40L in sepsis has
hardly been studied. In some animal models, an increase
in sCD40L was reported after the development of sepsis
[19,20]. In humans, higher sCD40L levels were found in
49 patients with meningococcal sepsis and 15 patients
with African tick bite fever compared with controls
[21,22]. In other small series with pulmonary tuberculo-
sis, higher sCD40L levels were found in patients with
more severe disease [23,24]. A study including 35 septic
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patients found higher circulating sCD40L levels in non-
surviving than in surviving patients [25]; however, there
are no data on the association between circulating
sCD40L levels and mortality of septic patients.
We hypothesized that circulating sCD40L levels could
be associated with an adverse outcome in patients with
severe sepsis. The primary objective of this study was to
determine the association between the circulating
sCD40L levels and mortality, and the secondary objec-
tive to determine the association between circulating
sCD40L, inflammatory and prothrombotic markers in
these patients.
Materials and methods
Design and subjects
A multicenter, observational, prospective study was car-
ried out in six Spanish ICUs. The study was approved
by the Institutional Review Boards of the six hospitals
and written informed consent from the patients or from
the family members was obtained. A total of 186
patients with severe sepsis and 50 age- and sex-matched
healthy controls were included.
The diagnosis of sepsis and severe sepsis was estab-
lished according to the International Sepsis Definitions
Conference [26]. Severe sepsis was defined as sepsis
complicated by organ dysfunction. Sepsis was defined as
a documented or suspected infection (defined as a
pathologic process induced by a microorganism) and
some of the following parameters: I) General para-
meters: fever (core temperature higher than 38.3°C),
hypothermia (core temperature lower than 36.0°C),
tachycardia (heart rate higher than 90 beats/minute),
tachypnea (respiratory rate higher than 30 breaths/min-
ute), altered mental status, significant edema or positive
fluid balance (higher than 20 ml/kg over 24 hours),
hyperglycemia (plasma glucose higher than 110 mg/dl)
in the absence of diabetes; II) Inflammatory parameters:
leukocytosis (white blood cell count higher than 12,000/
mm3), leukopenia (white blood cell count lower than
4,000 mm3), normal white blood cell count with a per-
centage of immature forms higher than 10%, plasma
C-reactive protein >2 standard deviations above the nor-
mal value, plasma procalcitonin >2 standard deviations
above the normal value; III) Hemodynamic parameters:
arterial hypotension (systolic blood pressure lower than
90 mmHg, mean arterial blood pressure lower than
70 mmHg, or decrease of systolic blood pressure from
the baseline higher than 40 mmHg), mixed venous oxy-
gen saturation higher than 70%, cardiac index higher
than 3.5 l/min/m2; IV) Organ dysfunction: arterial
hypoxemia (pressure of arterial oxygen/fraction inspired
oxygen (PaO2/FIO2) ratio <300), acute oliguria (urine
output <0.5 ml/kg/h for at least two hours), creatinine
increase ≥0.5 mg/dl, thrombocytopenia (platelet count
<100,000/mm3), hyperbilirubinemia (total bilirubin
>4 mg/dl); V) Tissue perfusion parameters: hyperlactate-
mia (>3 mmol/l), decreased capillary refill or mottling.
Exclusion criteria were: age <18 years, pregnancy, lac-
tation, human immunodeficiency virus (HIV), solid or
haematological tumour, or immunosuppressive, steroid
or radiation therapy.
Variables recorded
The following variables were recorded for each patient:
sex, age, diabetes mellitus, chronic obstructive pulmon-
ary disease (COPD), site of infection, creatinine, leuko-
cytes, lactatemia, platelets, Acute Physiology and
Chronic Health Evaluation II (APACHE II) score [27],
Sepsis-related Organ Failure Assessment (SOFA) score
[28]. We assessed survival at 30 days as the endpoint.
Blood samples were collected from 186 patients with
severe sepsis at the time of the diagnosis and from 50 age-
and sex-matched controls.
Serum levels of sCD40L
Venous blood samples were collected in serum separator
tubes (SST) and centrifuged within 30 minutes at
1,000*g for 15 minutes. The serum was removed and
frozen at -80°C until measurement. Serum sCD40L
levels were assayed by specific ELISA (Bender MedSys-
tems, Vienna, Austria) according to the manufacturer’s
instructions in the Atherosclerosis Research Laboratory
of CIMA-University of Navarra (Pamplona, Spain).
Plasma levels of TF
Venous blood samples were collected in citrate collected
plasma tubes and centrifuged within 30 minutes at
1,000*g for 15 minutes. The plasma was removed and
frozen at -80°C until measurement. Assays for TF anti-
gen were performed by specific ELISA (Imubind Tissue
Factor ELISA™, American Diagnostica, Inc, Stanford,
CT, USA) in the Laboratory Department of the Hospital
Universitario de Canarias (La Laguna, Santa Cruz de
Tenerife, Spain).
Serum levels of TNF-a and IL-10
Serum separator tubes (SST) were used to determine
TNF-a and IL-10 serum levels. Venous blood samples
were taken and centrifuged within 30 minutes at 1,000 g
for 15 minutes, and the serum was removed and frozen
at -80°C until measurement. TNF-a and IL-10 serum
levels were measured by a solid-phase, chemiluminiscent
immunometric assay kits (Immulite®, Siemens Health-
care Diagnostics Products, Llanberis, UK) in the Labora-
tory Deparment of the Hospital Universitario de
Canarias (La Laguna, Santa Cruz de Tenerife, Spain).
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Statistical analysis
In a pilot study with 30 patients with severe sepsis, we
found that surviving patients show lower circulat-
ing levels of sCD40L (3.83 ± 1.44 ng/mL) than non-
survivors (4.37 ± 1.52 ng/mL). We calculated to
include 186 patients in a cohort study to demonstrate
significant differences in the circulating levels of
sCD40L between groups, for a power of 80% and a 5%
type I error rate.
Continuous variables are reported as medians and
interquartile ranges. Categorical variables are reported
as frequencies and percentages. Comparisons of contin-
uous variables between groups were carried out using
Wilcoxon-Mann-Whitney test. Comparisons between
groups on categorical variables were carried out with
chi-square test. The association between continuous
variables was carried out using Spearman’s rank correla-
tion coefficient or Spearman’s rho coefficient. The cut-
off 3.5 ng/mL was selected using a likelihood method as
previously described [29]. Receiver operation character-
istic (ROC) curves using lactate, APACHE score,
sCD40L ≥3.5 ng/mL as independent variables, and exi-
tus at 30 days as a dependent variable were obtained.
To calculate the standard error of the area under the
curves we used the method of Delong et al. [30]. Survi-
val curves at 30 days, using sCD40L levels ≥ or lower
than 3.5 ng/mL, were represented using the Kaplan-
Meier method and were compared by log-rank test.
Multivariate logistic regression analysis was applied to
determine the independent contribution of sCD40L
levels, lactate levels, APACHE-II score and thrombocy-
topenia to the prediction of the mortality during the 30-
day period. Odds ratio and its 95% confidence intervals
were calculated as measurement of the clinical impact
of the predictor variables. A P-value of less than 0.05
was considered statistically significant. Statistical ana-
lyses were performed with SPSS 17.0 (SPSS Inc., Chi-
cago, IL, USA), NCSS 2000 (Kaysville, UT, USA), and
Statistic 8.0 (Tulsa, OK, USA).
Results
Baseline characteristics of 186 patients with severe sepsis
and 50 age- and sex-matched controls are shown in
Table 1. Higher sCD40L levels were observed in the
group of patients with severe sepsis compared with con-
trols (P = 0.01) (Table 1).
Non-surviving septic patients (n = 62) showed higher
sCD40L levels (P = 0.04) than survivors (n = 124) after
the 30-day follow-up. Non-surviving patients also
showed a higher incidence of diabetes mellitus (P =
0.02), higher lactatemia (P < 0.001), higher SOFA (P <
0.001) and APACHE-II (P < 0.001) scores, and lower
platelet count (P = 0.002) and IL-10 (P < 0.001) than
surviving patients (Table 2).
We did not find differences in 30-day survival between
those patients that received statins before sepsis com-
pared with those that did not receive statins (Table 2).
After the diagnosis of sepsis, none of the patients con-
tinued receiving statins.
We did not find significant differences in sCD40L
serum levels according to sex, diabetes mellitus status,
COPD, use of statins before sepsis diagnosis, personal
history of ischemic heart disease, need for mechanical
ventilation and presence of septic shock (Table 3).
Neither did we find significant differences in sCD40L
serum levels according to the site and source of infec-
tion (Table 4).
Logistic regression analysis showed that serum
sCD40L levels ≥3.5 ng/mL, lactatemia, APACHE-II
score and platelet count <60,000/mm3 were associated
with death at Day 30 (Table 5).
Survival analysis showed that patients with sCD40L
levels ≥3.5 ng/mL presented higher mortality during
the 30-day period than patients with lower levels
(Chi-square: 4.50; P = 0.03) (Figure 1).
The areas under the curves (AUC) for each predictor
of mortality were the following: sCD40L ≥3.5 ng/mL
(AUC = 0.58; 95% CI = 0.51 to 0.65; P = 0.03), lactate-
mia (AUC = 0.66; 95% CI = 0.59 to 0.73; P < 0.001) and
APACHE-II (AUC = 0.70; 95% CI = 0.62 to 0.76; P <
0.001) (Figure 2).
In the group of septic patients there were found an
association between serum sCD40L levels and tissue fac-
tor levels (rho = 0.26; P = 0.005) (Figure 3) and platelet
count (rho = 0.26; P < 0.001); but no association with
lactatemia, TNF-a and IL-10 levels, SOFA or APACHE-
II scores were observed (Table 6).
Discussion
The main finding of the present study is that serum
sCD40L levels were independently associated with mor-
tality at 30 days in a large series of septic patients.
We found higher serum sCD40L levels in patients
with severe sepsis than in healthy controls, in agree-
ment with previous studies [21,22,25]. We also found
higher circulating sCD40L levels in non-surviving than
in surviving patients, as previously reported by Nolan
et al. in a small series [25]. In addition, we found that
Table 1 Comparison between patients with severe sepsis
and controls
Controls
(n = 50)
Patients with severe
sepsis
(n = 186)
P
Female sex – n (%) 13 (26.0) 64 (33.3) 0.11
Age * (years) 57 (50 to 63) 60 (49 to 70) 0.39
sCD40L* (ng/ml) 3.29 (2.10 to 4.19) 3.97 (2.60 to 5.62) 0.01
*Median (25th to 75th percentiles).
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Table 2 Demographic and clinical parameters of survivors and non-survivors patients with severe sepsis
Survivors
(n = 124)
Nonsurvivors
(n = 62)
P
Female sex * 39 (31.5) 25 (40.3) 0.25
Age (years) † 55 (45 to 68) 63 (51 to 72) 0.19
Diabetes mellitus * 25 (20.2) 23 (37.1) 0.02
COPD * 19 (15.3) 9 (14.5) 0.99
Statins previous to sepsis diagnosis* 27 (21.8) 16 (25.8) 0.58
Ischemic heart disease* 14 (11.3) 7 (11.3) 0.99
Site of infection 0.90
Respiratory * 64 (51.6) 36 (58.0)
Abdominal * 29 (23.4) 13 (21.0)
Other sites* 31 (25.0) 13 (21.0)
Source of sepsis 0.73
Community* 93 (75.0) 49 (79.0)
Nosocomial extra-ICU* 12 (9.7) 7 (11.3)
Nosocomial intra-ICU* 19 (15.3) 6 (9.7)
Pa02/FI02 ratio
† 162 (107 to 260) 164 (96 to 228) 0.18
Creatinine (mg/dl) † 1.2 (0.8 to 1.9) 1.4 (0.9 to 2.8) 0.06
Bilirubin (mg/dl) † 0.9 (0.6 to 1.6) 0.9 (0.5 to 2.0) 0.64
Leukocytes/mm3 † 14200 (9200 to 18700) 15850 (9050 to 22525) 0.34
Lactatemia (mmol/L) † 1.7 (1.0 to 3.5) 3.9 (1.3 to 6.7) <0.001
Platelet count*103/mm3 † 199 (136 to 270) 139 (79 to 218) 0.002
APACHE-II score † 19 (14 to 23) 23 (18 to 29) <0.001
SOFA score † 9 (7 to 11) 12 (9 to 14) <0.001
Mechanical ventilation* 102 (82.3) 58 (93.5) 0.04
Septic shock* 105 (84.7) 57 (91.9) 0.24
sCD40L (ng/ml) † 3.78 (2.51 to 5.38) 4.42 (3.05 to 6.09) 0.04
Tissue factor (pg/ml) † 123 (99 to 163) 120 (96 to 150) 0.56
TNF-alpha (pg/ml) † 32 (20 to 50) 39 (18 to 79) 0.38
IL-10 (pg/ml) † 10 (6 to 36) 53 (7 to 169) <0.001
*Variable expressed as frequency (%); †variable expressed as median (25th to 75th percentiles).
APACHE, Acute Physiology and Chronic Health Evaluation; COPD, chronic obstructive pulmonary disease; IL, interleukin; Pa02/FI02, pressure of arterial oxygen/
fraction inspired oxygen; SOFA, Sepsis-related Organ Failure Assessment score; TNF, tumour necrosis factor.
Table 3 Serum levels of sCD40L according to clinical variables
Yes patient number and sCD40L levels Non patient number and sCD40L levels P
Female (n = 64)
4.39 (2.77 to 5.59)
(n = 122)
3.77 (2.51 to 6.02)
0.47
Diabetes Mellitus (n = 48)
3.97 (2.81 to 5.38)
(n = 134)
4.08 (2.59 to 6.02)
0.85
COPD* (n = 28)
4.35 (2.60 to 5.23)
(n = 154)
3.97 (2.65 to 6.02)
0.68
Statins previous to sepsis diagnosis (n = 43)
3.84 (2.60 to 5.65)
(n = 139)
4.10 (2.69 to 5.70)
0.81
Ischemic heart disease (n = 21)
4.10 (2.73 to 6.06)
(n = 162)
3.97 (2.62 to 5.60)
0.74
Mechanical ventilation (n = 160)
4.75 (3.55 to 6.85)
(n = 26)
3.85 (2.59 to 5.59)
0.09
Septic shock (n = 162)
4.54 (2.78 to 6.70)
(n = 24)
3.92 (2.60 to 5.60)
0.16
Survivors at 30 days (n = 124)
3.78 (2.51 to 5.38)
(n = 62)
4.42 (3.05 to 6.09)
0.04
*COPD, chronic obstructive pulmonary disease.
Lorente et al. Critical Care 2011, 15:R97
http://ccforum.com/content/15/2/R97
Page 4 of 8
serum sCD40L levels ≥3.50 ng/mL were associated with
higher death during the 30-day period in the multiple
logistic regression analysis. Impaired prognosis was
previously reported in patients with acute coronary
artery syndrome and higher sCD40L levels [31]; how-
ever, our study is the first reporting an impaired prog-
nosis in patients with severe sepsis and higher sCD40L
levels.
The role of sCD40L in sepsis remains unclear; but it is
possible that there are similarities with findings observed
in coronary artery disease [2]. CD40L is stored in a-
granules in unstimulated platelets but rapidly translo-
cates to the platelet surface when platelets are activated,
where it is cleaved and released into circulation as
sCD40L. The sCD40L binds to circulating monocytes
through its receptor CD40, promoting their adhesion to
vascular endothelium. The sCD40L also binds to CD40
on endothelial cell surfaces. Activated endothelial cells
produce the overexpression of transcriptional factors
such as nuclear factor-kappa B (NF-kß) [32], with subse-
quent up-regulation of proinflammatory and prothrom-
botic factors. Thus, sCD40L could have prothrombotic
effects via induction of TF [8-11], diminishing thrombo-
modulin expression [10,11], and binding to the glyco-
protein IIb/IIIa platelet receptor [12,13]. All these effects
could facilitate the development of vascular thrombosis,
organ dysfunction and death.
We report for first time an association between
sCD40L and TF levels in patients with severe sepsis,
which has been previously described in culture of vascu-
lar endothelial cells [8-11]. However, the observed asso-
ciation between sCD40L levels and mortality could not
been explained by the TF levels, since there were no sig-
nificant differences between non-surviving and surviving
patients. It is possible that other reported prothrombotic
effects of sCD40L, such as reduced thrombomodulin
expression [10,11] and binding to the glycoprotein IIb/
IIIa platelet receptor [12,13] could lead to vascular
Table 4 Serum levels of sCD40L according to the site and
source of infection
Patient number and sCD40L levels P
Site of infection 0.52
Respiratory (n = 100)
4.21 (2.81 to 6.09)
Abdominal (n = 42)
3.85 (2.59 to 5.36)
Other sites (n = 44)
3.83 (2.51 to 5.52)
Source of sepsis 0.38
Community (n = 142)
3.83 (2.55 to 5.46)
Nosocomial extra-ICU (n = 19)
4.70 (3.01 to 6.84)
Nosocomial intra-ICU (n = 25)
4.39 (2.91 to 6.18)
Table 5 Multiple logistic regression analysis of variables
to predict 30-day mortality
Variable Odds Ratio 95% Confidence Interval P
sCD40L levels
>3.5 ng/mL
2.35 1.16 to 4.76 0.02
Lactatemia 1.19 1.06 to 1.34 0.004
APACHE-II 1.05 1.001 to 1.10 0.04
Figure 1 Survival curves at 30 days using sCD40L levels higher
or lower than 3.5 ng/mL.
Figure 2 Receiver operation characteristic analysis using
sCD40L levels ≥ 3.5 ng/mL, APACHE-II and lactatemia as 30-
days mortality predictors.
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thrombosis and, finally, death in patients with severe
sepsis.
We found a positive association between serum
sCD40L levels and platelet count, possibly because pla-
telets are the major source of sCD40L in circulation
[4,5]. However, we did not find this association in
thrombocytopenic patients, which may be explained by
different underlying mechanisms in septic patients
[33,34], such as immune destruction by platelet antibo-
dies, hematophagocytosis in the bone marrow, reduced
production due to bone marrow depression and non-
immune destruction by the interaction of activated pla-
telets with endothelium.
We failed to find an association between sCD40L
levels and sepsis severity criteria such as lactatemia,
APACHE II score, SOFA score, TNF-a or IL-10 levels.
This is in agreement with the results by Nolan et al.
[25] reporting no correlation between sCD40L and the
concentrations of IL-6, IL-12 or APACHE II. The lack
of correlation may be due to a true absence of relation-
ship or that sCD40L levels are underestimated in more
severe disease (for example, dilution, leakage to the
intersticial space and urin, increased uptake at sites of
inflammation, and so on). In addition, sCD40L would
most likely response earlier to changes in inflammatory
activity that the APACHE, which is a composite of mul-
tiple parameters.
Whereas the strength of our study was the relatively
large sample size compared with previous reports asses-
sing sCD40L levels in septic patients, some limitations
should be recognized. We determined a single testing
point for sCD40L levels and we were, therefore, unable
to establish the time course of serum sCD40L levels.
Data on other coagulation factors were not analyzed. We
determined sCD40 levels only in serum and not in
plasma samples to evaluate possible differences due to
there has been reported higher sCD40L levels in serum
than in plasma levels [35], and in platelet rich plasma
than in platelet poor plasma [36,37]. There has been
reporting the association between sCD40L levels and
other cytokines as IL-12 or interferon-gamma; however,
we have not explored this possible association [6,38].
Neither, we have explored procalcitonin to determine its
association with sCD40L levels. There are been reported
an association between sCD40L levels and severity of
acute coronary artery syndrome [31] and between tropo-
nin and severity of sepsis [39-41]; however, we have not
investigated markers of cardiac damage to explore its
association with sCD40L levels. The time until the diag-
nosis of sepsis can influence the levels of sCD40L
observed; however, we have not report it. The serum
blood samples for the determination of sCD40L were
obtained at moment of sepsis diagnosis and APACHE II
was calculated at 24 hours of admission to ICU; thus, we
did know if this time-gap can affect in the association
between both variables. We have not found significant
Figure 3 Relationship between sCD40L and tissue factor levels.
Table 6 Correlations between sCD40L levels (ng/ml) and lactatemia, APACHE-II, platelet count, TNF-alpha, interleukin-
10 and tissue factor
All patients
(n = 186)
Patients with platelet count ≥ 100,000/mm3
(n = 138)
Patients with platelet count < 100,000/mm3
(n = 48)
Lactatemia (mmol/L) Rho = -0.11
P = 0.15
Rho = -0.06
P = 0.50
Rho = -0.08
P = 0.61
APACHE-II (punctuation) Rho = -0.03
P = 0.66
Rho = -0.07
P = 0.40
Rho = 0.20
P = 0.18
Platelet count (cells/mm3) Rho = 0.25
P < 0.001
Rho = 0.22
P = 0.01
Rho = 0.09
P = 0.52
TNF-alpha† (pg/ml) Rho = -0.08
P = 0.31
Rho = 0.27
P = 0.76
Rho = -0.16
P = 0.28
Interleukin-10 (pg/ml) Rho = -0.05
P = 0.49
Rho = 0.03
P = 0.70
Rho = -0.14
P = 0.35
Tissue factor (pg/ml) Rho = 0.28
P = 0.002
Rho = 0.29
P = 0.006
Rho = 0.17
P = 0.42
*APACHE, Acute Physiology and Chronic Health Evaluation; †TNF, tumour necrosis factor.
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difference in the survival at 30 days with the use of sta-
tins previously to the diagnosis of severe sepsis; and it
was not possible to explore the effect of this agent group
during the sepsis because in all patients was it suspended.
From a therapeutic perspective, the use of sCD40L
modulators could be used as a new class of drugs for
the treatment of severe sepsis [42-46]. In one study
including patients with coronary artery disease, the use
of statins decreased circulating sCD40L levels [42].
Besides, the results of some studies suggest that the use
of statins could improve the prognosis in patients with
infectious episodes [43-46]. However, in some human
and animal studies the use of antibody against CD40L
was associated with platelet activation and thromboem-
bolic complications [47-49].
Conclusions
In conclusion, circulating sCD40L levels are increased in
septic patients and are independently associated with
mortality in these patients; thus, its modulation could
represent an attractive therapeutic target.
Key messages
• Patients with severe sepsis showed higher circulat-
ing sCD40L levels than healthy controls.
• Non-survivor septic patients showed higher circu-
lating sCD40L levels than survivor ones.
• Modulation of circulating sCD40L levels could
represent an attractive therapeutic target in sepsis.
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